Sema4 Holdings Corporation (SMFR) Quote

SMFR...MGS..READY TO RUMBLE!!

SMFR here we go...monster in the making

SMFR breaking out

Nice DD thank you for your work on this one

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch


Settlement Date/Short Interest/Percent Change/
Average Daily Share Volume/Days to Cover

04/29/2022 37,015,515 6.21 4,258,195 8.69
04/14/2022 34,851,727 1.60 4,006,302 8.70
03/31/2022 34,302,508 (3.81) 3,527,731 9.72
03/15/2022 35,660,370 (2.73) 4,435,088 8.04
02/28/2022 36,660,502 0.02 4,275,193 8.58
02/15/2022 36,654,794 4.85 5,152,587 7.11
01/31/2022 34,960,099 12.00 12,988,554 2.69
01/14/2022 31,214,431 9.40 4,667,043 6.69
12/31/2021 28,531,899 50.48 5,170,956 5.52
12/15/2021 18,959,968 (4.61) 6,314,561 3.00
11/30/2021 19,876,928 (14.62) 4,816,541 4.13
11/15/2021 23,281,508 1.21 12,627,834 1.84
10/29/2021 23,002,454 (1.39) 2,188,511 10.51
10/15/2021 23,325,568 6.09 1,985,365 11.75
09/30/2021 21,985,689 0.18 2,866,220 7.67
09/15/2021 21,946,379 (6.58) 2,095,240 10.47
08/31/2021 23,492,189 15.09 4,189,182 5.61
08/13/2021 20,412,654 4.52 3,267,018 6.25
07/30/2021 19,530,826 0.43 2,978,611 6.56
07/15/2021 19,447,243 (14.18) 3,779,246 5.15
06/30/2021 22,659,534 (8.59) 6,584,990 3.44
06/15/2021 24,787,930 (22.71) 6,152,172 4.03
05/28/2021 32,072,669 8.73 5,240,967 6.12
05/14/2021 29,497,586 0.06 2,730,948 10.

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch


Settlement Date/Short Interest/Percent Change/
Average Daily Share Volume/Days to Cover

03/31/2022 4,881,452 4.41 1,931,588 2.53
03/15/2022 4,675,255 (6.03) 1,112,704 4.20
02/28/2022 4,975,388 8.40 907,484 5.48
02/15/2022 4,589,929 (14.87) 1,591,230 2.88
01/31/2022 5,391,503 (13.40) 3,212,753 1.68
01/14/2022 6,225,885 (20.95) 1,561,926 3.99
12/31/2021 7,875,591 5.45 1,909,346 4.12
12/15/2021 7,468,604 (4.23) 1,448,825 5.15
11/30/2021 7,798,438 (1.99) 1,418,961 5.50
11/15/2021 7,956,557 (7.44) 1,030,830 7.72
10/29/2021 8,595,730 0.19 595,530 14.43
10/15/2021 8,579,485 (11.90) 1,832,656 4.68
09/30/2021 9,738,886 (2.15) 1,868,222 5.21
09/15/2021 9,952,566 24.83 1,426,298 6.98
08/31/2021 7,972,924 57.97 1,754,538 4.54
08/13/2021 5,047,217 79.26 1,208,409 4.18
07/30/2021 2,815,510 (17.24) 807,439 3.49
07/15/2021 3,402,197 47.06 614,404 5.54
06/30/2021 2,313,495 8.42 961,956 2.40
06/15/2021 2,133,877 28.44 787,086 2.71
05/28/2021 1,661,329 12.00 435,170 3.82
05/14/2021 1,483,298 (31.15) 835,435 1.78
04/30/2021 2,154,239 26.81 421,288 5.11
04/15/2021 1,698,762 (6.69) 700,333 2.43

Institutional Shares (Long) 119,435,731 - 49.24% (ex 13D/G) -

Per Fintel:
https://fintel.io/so/us/smfr

Considered "insiders":

Shares Outstanding 242,578,824 shares
Insider Shares 120,429,654 shares
Insider Ownership 49.65%
Total Insiders 42

https://fintel.io/n/us/smfr

I discovered this company through this PR - just beginning to investigate:



STAMFORD, Conn. and MIAMI, Jan. 18, 2022 (GLOBE NEWSWIRE) — Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a multinational biopharmaceutical and diagnostics company, today announced they have signed a definitive agreement for Sema4 to acquire OPKO’s wholly owned subsidiary, GeneDx, Inc. (“GeneDx”), a leader in genomic testing and analysis, from OPKO. The acquisition strengthens Sema4’s leadership, growth, and scale for its market-leading health intelligence and genomic screening offerings. Together, Sema4 and GeneDx will be one of the largest and most advanced providers of genomic clinical testing in the U.S., with a projected $350 million in pro forma 2022 revenue.

Following completion of the acquisition, Sema4 will be optimally positioned to partner with health systems and biopharma companies to further transform the standard of care throughout the patient health journey. GeneDx’s leadership in rare disease diagnostic and exome sequencing services brings more than 300,000 clinical exomes and over 2.1 million expertly annotated phenotypes to strengthen Sema4’s 12 million de-identified clinical records for Centrellis®, its proprietary health intelligence platform, and Traversa™, its comprehensive genomic analysis platform for optimizing health screenings. Sema4 plans to leverage this combined health information database to transform patient care and therapeutic development and enable precision medicine for all.

more..

https://www.bioreference.com/sema4-to-acquire-genedx/